Safety of inhaled corticosteroids

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Corticosteroids are effective asthma controllers but oral administration causes systemic side-effects.
• Inhaled corticosteroids (ICS) offer a localized delivery method to minimize systemic exposure.
• Concerns exist regarding potential systemic activity and side-effects of ICS.

Purpose of the Study:

• To evaluate the safety and efficacy of inhaled corticosteroids in asthma management.
• To compare the side-effect profile of ICS with systemic steroids and bronchodilators.
• To determine the threshold for clinically significant systemic activity with ICS.

Main Methods:

• Review of clinical data and published literature on inhaled corticosteroid use in asthma.
• Analysis of systemic activity detection via sensitive tests at varying beclomethasone dipropionate dosages.
• Assessment of local side-effects and long-term safety data.

Main Results:

• ICS are effective for asthma control, with minimal systemic side-effects at typical doses (400-800 micrograms/day).
• Systemic activity becomes more detectable and clinically significant above 1.5-2.0 mg/day.
• Local side-effects like hoarseness and thrush are occasional; no opportunistic infections or bronchial damage reported.
• Extensive global use over a decade confirms a favorable safety profile.

Conclusions:

• Inhaled corticosteroids provide safe and effective asthma treatment, especially when bronchodilators are insufficient.
• ICS offer a superior safety profile compared to intensive bronchodilator therapy or systemic steroids.
• The risk-benefit balance favors ICS, allowing for higher doses when necessary without significant systemic risks.